183 related articles for article (PubMed ID: 27354621)
1. Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer.
Cho O; Chun M; Chang SJ; Oh YT; Noh OK
Anticancer Res; 2016 Jul; 36(7):3541-7. PubMed ID: 27354621
[TBL] [Abstract][Full Text] [Related]
2. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation.
Kim TE; Park BJ; Kwack HS; Kwon JY; Kim JH; Yoon SC
J Obstet Gynaecol Res; 2012 Nov; 38(11):1315-20. PubMed ID: 22612778
[TBL] [Abstract][Full Text] [Related]
5. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
6. Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis.
Lee YY; Park W; Huh SJ; Yoon A; Park JY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
Anticancer Res; 2013 Oct; 33(10):4675-81. PubMed ID: 24123048
[TBL] [Abstract][Full Text] [Related]
7. [Outcomes and prognostic factors of advanced squamous cervical cancer after concurrent chemoradiotherapy].
Binbin T; Lingying W; Manni H; Jusheng A; Ning L
Zhonghua Fu Chan Ke Za Zhi; 2014 May; 49(5):348-54. PubMed ID: 25030731
[TBL] [Abstract][Full Text] [Related]
8. Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.
Marconi DG; Fregnani JH; Rossini RR; Netto AK; Lucchesi FR; Tsunoda AT; Kamrava M
BMC Cancer; 2016 Jul; 16():556. PubMed ID: 27469349
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
[TBL] [Abstract][Full Text] [Related]
10. The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy.
Onal C; Yildirim BA; Guler OC; Mertsoylu H
Int J Gynecol Cancer; 2018 Oct; 28(8):1553-1559. PubMed ID: 30247248
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort.
Endo D; Todo Y; Okamoto K; Minobe S; Kato H; Nishiyama N
J Gynecol Oncol; 2015 Jan; 26(1):12-8. PubMed ID: 25310853
[TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
[TBL] [Abstract][Full Text] [Related]
13. Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma.
Cho O; Chun M; Oh YT; Noh OK; Chang SJ; Ryu HS; Lee EJ
Tumour Biol; 2017 Oct; 39(10):1010428317733144. PubMed ID: 29022484
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
Lim A; Sia S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial.
Umayahara K; Takekuma M; Hirashima Y; Noda SE; Ohno T; Miyagi E; Hirahara F; Hirata E; Kondo E; Tabata T; Nagai Y; Aoki Y; Wakatsuki M; Takeuchi M; Toita T; Takeshima N; Takizawa K
Gynecol Oncol; 2016 Feb; 140(2):253-8. PubMed ID: 26701414
[TBL] [Abstract][Full Text] [Related]
16. Lymphopenia and its association with survival in patients with locally advanced cervical cancer.
Wu ES; Oduyebo T; Cobb LP; Cholakian D; Kong X; Fader AN; Levinson KL; Tanner EJ; Stone RL; Piotrowski A; Grossman S; Roche KL
Gynecol Oncol; 2016 Jan; 140(1):76-82. PubMed ID: 26571200
[TBL] [Abstract][Full Text] [Related]
17. HPV genotypes predict survival benefits from concurrent chemotherapy and radiation therapy in advanced squamous cell carcinoma of the cervix.
Wang CC; Lai CH; Huang YT; Chao A; Chou HH; Hong JH
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e499-506. PubMed ID: 22889667
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928
[TBL] [Abstract][Full Text] [Related]
19. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]